Podcast Summary: Short Wave – "Could this vaccine trial mean a future without HIV?"

Date: February 16, 2026
Host: Nate Rodd (filling in for Emily Kwong & Regina Barber)
Guest: Ari Daniel (Freelance Science Reporter), Prof. Penny Moore, Dr. Linda-Gail Bekker, Nunu Mkize, Amelia Nfiki, and Nandeep Hamongo

Overview

This episode dissects the remarkable and often fraught journey behind a major HIV vaccine trial in South Africa. It covers the two-decade-long research foundation, setbacks due to U.S. foreign aid freezes, and the perseverance of local scientists and communities in moving HIV research forward, even with drastically reduced funding. The episode highlights the new vaccine's scientific roots, the pivotal role of South African women, and what a real-world end to HIV could look like.

Key Discussion Points and Insights

The Research Foundation: Two Decades of Samples

• Setting the Scene: Ari Daniel visits the National Institute for Communicable Diseases in Johannesburg, South Africa, where virologist Penny Moore and her team have collected blood samples from the same group of 117 South African women for 20 years.
  • [01:06] Penny Moore: "These are the freezers that contain samples that are the basis of everything we do in the lab. Our freezers are named after the seven dwarfs."
  • [01:55] Nate: "You mean they collected blood from the same group of women for 20 years?"
  • [02:02] Penny Moore: "They live in communities most ravaged by HIV. They donate their samples because they hope to see an end to an epidemic that is really, really real for them."
• These samples have helped map HIV's evolution and response, aiding not only HIV but other diseases like COVID-19 and cancer.

Near-Derailment: The U.S. Aid Freeze

• Zanzibar Proposal Meeting: Researchers gathered in Zanzibar, energized by a $45 million USAID grant to develop a vaccine tailored for diverse African communities.
  • [06:15] Ari: "Penny and her colleagues had gotten a $45 million grant from USAID... The goal was to get teams across the continent to collaborate."
• Funding Crisis: News breaks at the meeting that President Trump’s 2020 executive order freezes most foreign aid, including their grant.
  • [07:06] Penny Moore: "I remember at the end of the meeting, USAID colleagues saying to me, I'm not sure if I'll see you again. I completely underestimated how much it would gut the program."
  • [07:38] Dr. Linda-Gail Bekker: "When the funding collapsed, I cycled through the stages of grief… Angry because we'd worked damn hard…"

Recovery and Adaptation: Scaling Down, Not Stopping

• Desperate Measures: The team quickly sought new funding and eventually secured $2.2 million from the South African Medical Research Council and Gates Foundation.
  • [08:08] Dr. Linda-Gail Bekker: "This matters too much to not finish the work. We brought out the begging bowl."
• New Scope: The trial shrinks to a South Africa-only pilot, sacrificing the chance to study virus variants across Africa.
  • [08:54] Penny Moore: "It's a bare bones version. We will still get the answer, but it's going to cost us time, years. Which is not trivial because people are getting infected with this virus constantly."

The Science: Broadly Neutralizing Antibodies

• Breakthrough: Scientists found that some of the 117 women developed rare "broadly neutralizing antibodies" (bNAbs) capable of stopping nearly any strain of HIV worldwide.
  • [09:50] Penny Moore: "A broadly neutralizing antibody could stop my virus and could stop your virus and could stop an HIV virus from any other person. In many cases, up to 90% of global viruses could be stopped by one antibody."
  • [10:03] Nate (jokingly): "So this is like a super antibody! Does it wear a cape?"
• The Goal: Develop a vaccine that educates the immune system to produce these bNAbs early, offering protection before HIV infection.

The Community: Local Leadership, Local Hope

• Community Engagement: In Cape Town, community liaison officer Amelia Nfiki introduces the vaccine trial to 20 local women, including 25-year-old Nandeep Hamongo, who describes the dire need for HIV prevention.
  • [11:51] Nandeep Hamongo: "Most of us are scared of getting HIV, which is why I’d happily be involved in the research… I’m over the moon, man. I’m over the moon. Yes."
  • [12:08] Nandeep Hamongo on a world without HIV: "Living free? Yeah."
• Empowerment: The pride is palpable among both researchers and participants, underscoring local agency and ambition.
  • [11:22] Amelia Nfiki: "This is a great opportunity for South Africa to prove that we can do things in South Africa, for South Africa, with South African financing."

The Present and Looking Ahead

• Trial Status: The first shots went into arms in January, with the study rolling out over the coming months.
  • [12:26] Ari Daniel: "It already started, Nate, in January, and it's going to continue for some months."
• A World Without HIV: The optimism from those involved is met with measured scientific caution but a sense of unprecedented progress.

Notable Quotes & Memorable Moments

• [02:34] Penny Moore: "The amount we have learned from these freezers, it's just astonishing."
• [03:00] Dr. Linda-Gail Bekker (on setback): "In many ways, we’ve kind of had our legs cut off even as we're beginning to run the sprint."
• [07:54] Dr. Linda-Gail Bekker: "Angry because we'd worked damn hard. We'd won this grant, and we were doing what we said we would do."
• [08:54] Penny Moore: "It's a bare bones version. We will still get the answer, but it's going to cost us time, years. Which is not trivial because people are getting infected with this virus constantly."
• [09:50] Penny Moore: "A broadly neutralizing antibody could stop an HIV virus from any other person. And in many cases, up to 90% of global viruses could be stopped by one antibody."
• [11:51] Nandeep Hamongo: "Most of us are scared of getting HIV, which is why I’d happily be involved in the research… I’m over the moon, man. I’m over the moon. Yes."

Timestamps for Important Segments

• [01:00-02:30] — Why the blood samples from South African women matter
• [04:46-06:36] — The Zanzibar "high-point" meeting and research momentum
• [07:04-08:14] — U.S. foreign aid freeze and the program's near collapse
• [08:30-09:05] — Scaling back ambitions and the implications
• [09:30-10:51] — Discovery and implications of broadly neutralizing antibodies
• [10:56-12:26] — Launching the vaccine trial in South African communities
• [12:26-12:37] — Where the trial stands and next steps

Conclusion

This episode of Short Wave offers a human-centered, hopeful look at the ongoing fight for an HIV vaccine in Africa. Despite political, financial, and scientific obstacles, South African researchers and communities remain undeterred, forging ahead with less funding but undiminished resolve. The trial, now underway, is a vital step on the road to ending HIV—and a testament to local leadership and scientific perseverance.

For more stories like this, follow "Short Wave" on your podcast app of choice.